https://endpts.com/advocates-experts-cry-foul-over-amylyxs-new-als-drug-citing-issues-with-price-phiii-commitment/
0
0
9/30/22 at 3:51pm
Organization
Endpoints News
Author
Max Gelman
61 words
0
Comments
Not 24 hours after earning the first ALS drug approval in five years, Amylyx Pharmaceuticals’ Relyvrio is already drawing scrutiny. And it’s coming from multiple fronts. In an investor call Friday morning, Amylyx revealed that it would charge about $158,000 p…
You are the first to view
Create an account
or login to join the discussion